A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Status:
Active, not recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multicentre dose escalation/expansion study to assess safety and
tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a
tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2)
pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients
with various solid tumours that have spread to the liver, or alternatively originating in the
liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only
include patients with HCC.